Is Pharma Running Out of Brainy Ideas?
Abstract
Recent cutbacks raise concerns about the future of drug development for nervous system disorders.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
It is possible to provide realistic estimates of power and to predict the number of new associations for each increment in sample size.
“It is possible to provide realistic estimates of power and to predict the number of new associations for each increment in sample size 128,129,140”
From Genetic architectures of psychiatric disorders: the emerging picture and its implications (2012) · cites this paper as [140]
Cited by
Sorted by citations
Toward the future of psychiatric diagnosis: the seven pillars of RDoC
Cuthbert, B. N., & Insel, T. R. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-126 · Cited by 3,053 · see citing works
Genetic architectures of psychiatric disorders: the emerging picture and its implications
Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3240 · Cited by 1,177 · see citing works
Using Neuroscience to Help Understand Fear and Anxiety: A Two-System Framework
LeDoux, J. E., & Pine, D. S. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16030353 · Cited by 1,035 · see citing works
“The pharmaceutical industry has concluded that the probability of discovering new treatments is low (2, 110), and it has curtailed investment in future psychotropic medication discovery.”
BackgroundThe Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 881 · see citing works
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739 · see citing works
“For the brave new psychiatry of the future – that many would like to see (Miller, 2010) – decisions about whether to passively endure or actively address, may become increasingly pertinent.”
BackgroundUnderstanding the Higher-Order Approach to Consciousness
Brown, R., Lau, H., & LeDoux, J. E. (2019) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2019.06.009 · Cited by 573 · see citing works
“However, these efforts to develop novel agents through studies of animals have been so unsuccessful that the pharmaceutical industry has significantly scaled back research in this area [119].”
BackgroundLiu, R. T., Walsh, R. F. L., & Sheehan, A. E. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.03.023 · Cited by 564 · see citing works
“This is especially important given the increasing need for the development of novel psychopharmacological agents for these conditions (Hyman, 2012; Insel, 2015; Miller, 2010).”
BackgroundGribkoff, V. K., & Kaczmarek, L. K. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.021 · Cited by 379 · see citing works
“The failure rate for new drugs targeting important central nervous system (CNS) diseases is very high relative to most other areas of drug discovery, a fact reflected in the many pharmaceutical company CNS programs that have been disbanded or significantly reduced (Abbott, 2011; Miller, 2010).”
The Opioid Epidemic: Crisis and Solutions
Skolnick, P. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052534 · Cited by 307 · see citing works
The subjective experience of emotion: a fearful view
LeDoux, J. E., & Hofmann, S. G. (2018) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2017.09.011 · Cited by 268 · see citing works
“A major challenge for these approaches is accounting for the failure of studies using defensive behaviors in animals as means of drug-discovery to generate novel agents with clinical efficacy in treating fear and anxiety [6,28,29,62].”
BackgroundHyman, S. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003142 · Cited by 260 · see citing works
Pharmacogenetic approaches to the treatment of alcohol addiction
Heilig, M. A., Goldman, D. A., Berrettini, W. H., & O’Brien, C. P. (2011) · Nature reviews. Neuroscience · doi:10.1038/nrn3110 · Cited by 249 · see citing works
“Developing therapeutics that target these mechanisms will require a considerable investment, at a time when the willingness of the pharmaceutical industry to invest in drug development for behavioural disorders has diminishe”
BackgroundRodent models of post-traumatic stress disorder: behavioral assessment
Verbitsky, A., Dopfel, D., & Zhang, N. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0806-x · Cited by 250 · see citing works
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 251 · see citing works
“However, research and development in psychopharmacology—psychiatry’s primary mode of intervention—came to a halt in 2010 (Miller, 2010; Hyman, 2013).”
BackgroundEpigenetic GABAergic targets in schizophrenia and bipolar disorder
Guidotti, A., Auta, J., Chen, Y., Davis, J. M., Dong, E., Gavin, D. P., Grayson, D. R., Matrisciano, F., Pinna, G., Satta, R., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.021 · Cited by 220 · see citing works
Improving and Accelerating Drug Development for Nervous System Disorders
Pankevich, D. E., Altevogt, B. M., Dunlop, J., Gage, F. H., & Hyman, S. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.007 · Cited by 205 · see citing works
Medications development to treat alcohol dependence: a vision for the next decade
Litten, R. Z., Egli, M., Heilig, M. A., Cui, C., Fertig, J. B., Ryan, M. L., Falk, D. E., Moss, H. B., Huebner, R. B., & Noronha, A. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00454.x · Cited by 204 · see citing works
“Surprisingly, despite significant advances in the scientific discovery of new targets for medications, the likelihood of reaching FDA approval is no better now than it was 20 years ago (Miller, 2010).”
InfluentialPutting the “mental” back in “mental disorders”: a perspective from research on fear and anxiety
Taschereau‐Dumouchel, V., Michel, M., Lau, H. C., Hofmann, S. G., & LeDoux, J. E. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01395-5 · Cited by 182 · see citing works
Psychedelics in the treatment of unipolar mood disorders: a systematic review
Rucker, J., Jelen, L. A., Flynn, S. K., Frowde, K., & Young, A. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116679368 · Cited by 185 · see citing works
“Many pharmaceutical companies have ended research efforts into psychiatric disorders, and there are few novel agents in development(Hyman, 2013; Miller, 2010), leading some to look to history for inspiration.”
BackgroundPharmacological treatment of anxiety disorders: Current treatments and future directions
Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy‐Byrne, P. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.07.009 · Cited by 183 · see citing works
An allosteric modulator to control endogenous G protein-coupled receptors with light
Pittolo, S., Gómez‐Santacana, X., Eckelt, K., Rovira, X., Dalton, J. A. R., Goudet, C., Pin, J., Llobet, A., Giraldo, J., Llebaria, A., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1612 · Cited by 180 · see citing works
The NIMH experimental medicine initiative
Insel, T. R. (2015) · World Psychiatry · doi:10.1002/wps.20227 · Cited by 165 · see citing works
“While there has been progress in the development of devices and psychosocial treatments, psychopharmacology over the past decade appears to have stalled after four decades of exuberant growth (2).”
BackgroundNext-Generation Treatments for Mental Disorders
Insel, T. R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004873 · Cited by 161 · see citing works
Psychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155 · see citing works
A Comprehensive Family-Based Replication Study of Schizophrenia Genes
Åberg, K. A., Liu, Y., Bukszár, J., McClay, J. L., Khachane, A. N., Andreassen, O. A., Blackwood, D., Corvin, A. P., Djurovic, S., Gurling, H., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.288 · Cited by 150 · see citing works
“Identifying the specific genetic variants that increase susceptibility is crucial to improve our understanding of SCZ and has the potential to address the urgent need for new drug targets.(5) Although SCZ genetics have proven difficult, recent genome-wide association studies (GWASs) mega- and metaanalyses have suggest…”
BackgroundHickie, I. B., Naismith, S. L., Robillard, R., Scott, E. M., & Hermens, D. F. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-79 · Cited by 148 · see citing works
“More profoundly from a therapeutic perspective, it has contributed to the withdrawal of major pharmaceutical industry support for new drug development [7].”
Backgroundvan der Gronde, T., Groot, C. A. U., & Pieters, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182613 · Cited by 144 · see citing works
Comparability of behavioural assays using zebrafish larvae to assess neurotoxicity
Legradi, J., Abdellaoui, N., van Pomeren, M., & Legler, J. (2014) · Environmental Science and Pollution Research · doi:10.1007/s11356-014-3805-8 · Cited by 137 · see citing works
Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials
Vrijens, B., & Urquhart, J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.59 · Cited by 142 · see citing works
Importance of Drug Pharmacokinetics at the Site of Action
Rizk, M. L., Zou, L., Savić, R. M., & Dooley, K. E. (2017) · Clinical and Translational Science · doi:10.1111/cts.12448 · Cited by 132 · see citing works
Behavioral screening for neuroactive drugs in zebrafish
Rihel, J., & Schier, A. F. (2011) · Developmental Neurobiology · doi:10.1002/dneu.20910 · Cited by 126 · see citing works
Innovative solutions to novel drug development in mental health
Insel, T. R., Voon, V., Nye, J. S., Brown, V. J., Altevogt, B. M., Bullmore, E. T., Goodwin, G. M., Howard, R. J., Kupfer, D. J., Malloch, G., et al. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.022 · Cited by 124 · see citing works
LeDoux, J. E. (2021) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2021.0292 · Cited by 119 · see citing works
Hengartner, M. P., & Lehmann, S. N. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00101 · Cited by 115 · see citing works
“As a result, various pharmaceutical companies have withdrawn their investments from research on new psychiatric drugs (68).”
BackgroundA Single-Cell Model for Synaptic Transmission and Plasticity in Human iPSC-Derived Neurons
Meijer, M., Rehbach, K., Brunner, J., Classen, J., Lammertse, H. C. A., van Linge, L. A., Schut, D., Krutenko, T., Hebisch, M., Cornelisse, L. N., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.058 · Cited by 111 · see citing works
Quintana, D. S., Guastella, A. J., Westlye, L. T., & Andreassen, O. A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.166 · Cited by 107 · see citing works
New paradigms for treatment‐resistant depression
Zarate, C. A., Duman, R. S., Liu, G., Sartori, S. B., Quiroz, J. A., & Murck, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12223 · Cited by 108 · see citing works
Quintana, D. S., Westlye, L. T., Rustan, Ø. G., Tesli, N., Poppy, C. L., Smevik, H., Tesli, M., Røine, M., Mahmoud, R. A., Smerud, K. T., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.93 · Cited by 103 · see citing works
Novel glutamatergic drugs for the treatment of mood disorders
Murrough, J. W., Lapidus, K. A. B., & Soleimani, L. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36689 · Cited by 92 · see citing works
“After several unsuccessful attempts by the industry to develop drugs active at new molecular targets for mood disorders, several major pharmaceutical companies have recently eliminated or reduced R&D investment in neuroscience therapeutics.(9) The remaining programs tend to focus on ‘safe’ targets rather than potentia…”
Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward
Bradley, E., & Woolley, J. D. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.007 · Cited by 88 · see citing works
“, 2012) while development of new therapeutics in the field has slowed (Hyman, 2012; Miller, 2010), investigating novel potentially effective treatments is a critical task to reduce morbidity.”
Saavedra, J. M. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9754-6 · Cited by 91 · see citing works
“generative disorders during the last decades, and several major pharmaceutical companies have recently made the decision to substantially reduce or eliminate their CNS drug discovery operations (Miller 2010).”
BackgroundThe microbiome as a novel paradigm in studying stress and mental health.
Liu, R. T. (2017) · American Psychologist · doi:10.1037/amp0000058 · Cited by 89 · see citing works
“With the recent stagnation in the development of psychopharmacological agents for treating mental illness (Hyman, 2012; Insel, 2015; Miller, 2010), the need for the development of new treatment options is more pressing than ever.”
BackgroundBrinn, A., & Stone, J. M. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-036859 · Cited by 86 · see citing works
Biomimetic drug-delivery systems for the management of brain diseases
Chen, Y., Wei, C., Lyu, Y., Chen, H., Jiang, G., & Gao, X. (2019) · Biomaterials Science · doi:10.1039/c9bm01395d · Cited by 86 · see citing works
Besteher, B., Gaser, C., & Nenadić, I. (2020) · Neuropsychobiology · doi:10.1159/000501024 · Cited by 83 · see citing works
Governing through the Brain: Neuropolitics, Neuroscience and Subjectivity
Rose, N., & Abi-Rached, J. M. (2014) · The Cambridge Journal of Anthropology · doi:10.3167/ca.2014.320102 · Cited by 86 · see citing works
“The relative failure of this dream, on which so much pharmaceutical investment was based, has led to the withdrawal of several large pharmaceutical companies from psychiatric drug development (Miller 2010).”
BackgroundMorofuji, Y., & Nakagawa, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200224112534 · Cited by 83 · see citing works
Sherman, S. P., & Bang, A. G. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.031906 · Cited by 78 · see citing works
“New therapies for neurological indications have a high attrition rate, with only 8% ever making it to clinical trial (Miller, 2010).”
Millan, M. J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001496 · Cited by 78 · see citing works
“…of reimbursement for novel drugs from national institutions post-launch, in particular bearing in mind the comparatively low rate of success, yet high cost of development for central nervous system (CNS) drugs vs. other therapeutic areas (Brady et al., 2009; Miller, 2010; Nutt and Goodwin, 2011).”
BackgroundMedicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs
Choi, D. W., Armitage, R., Brady, L. S., Coetzee, T., Fisher, W. W., Hyman, S. E., Pande, A. C., Paul, S. M., Potter, W. Z., Roin, B. N., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.027 · Cited by 75 · see citing works
Experimental medication treatment approaches for depression
Ionescu, D., & Papakostas, G. I. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.33 · Cited by 76 · see citing works
Olanzapinium Salts, Isostructural Solvates, and Their Physicochemical Properties
Thakuria, R., & Nangia, A. K. (2013) · Crystal Growth & Design · doi:10.1021/cg400692x · Cited by 75 · see citing works
Modulation of Social Cognition via Hallucinogens and “Entactogens”
Preller, K. H., & Vollenweider, F. X. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00881 · Cited by 71 · see citing works
“2) Given that drug development in psychiatry has stagnated for decades, new therapeutic models are urgently needed (14).”
BackgroundAdvances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments
Castro, F., Martins, C., Silveira, M. J., Moura, R. P., Pereira, C. L., & Sarmento, B. F. C. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.001 · Cited by 69 · see citing works
Ancient Roots of Today’s Emerging Renaissance in Psychedelic Medicine
George, D. R., Hanson, R., Wilkinson, D., & Garcia‐Romeu, A. (2021) · Culture Medicine and Psychiatry · doi:10.1007/s11013-021-09749-y · Cited by 66 · see citing works
“…of Mental Health—the world’s largest funder of mental health research—from clinical trials to basic research (Reardon 2017; Lewis-Fernandez et al. 2016) and calculated decisions by pharmaceutical companies to pursue treatment for conditions with lower risks and higher profit-margins (Miller 2010).”
BackgroundIn Vitro Screening for Drug Repositioning
WILKINSON, G. F., & Pritchard, K. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114563024 · Cited by 66 · see citing works
Chowdhury, E. A., Noorani, B., Alqahtani, F., Bhalerao, A., Raut, S., Sivandzade, F., & Cucullo, L. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20985946 · Cited by 70 · see citing works
Cummings, J. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.020 · Cited by 65 · see citing works
Psychiatric drug development: diagnosing a crisis.
Hyman, S. E. (2013) · Europe PMC (PubMed Central) · Cited by 89 · see citing works
Drug Delivery to the Brain: Recent Advances and Unmet Challenges
Bhunia, S., Kolishetti, N., Vashist, A., Yndart, A., Brooks, D., & Nair, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122658 · Cited by 69 · see citing works
“%) of drugs developed to be translated for clinical use [4].”
BackgroundNeuroscience and the future for mental health?
Rose, N. (2015) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796015000621 · Cited by 64 · see citing works
“…few novel ideas, and almost nothing that gives any hope for a transformation in the treatment of mental illness ’ (see also de Leon, 2014, quoted in Miller, 2010; O ’ Brien et al. 2014) (for recent discussions, see the article in the New York Times by Richard Friedman: http://…”
Arns, M. (2012) · Journal of Neurotherapy · doi:10.1080/10874208.2012.677664 · Cited by 60 · see citing works
“Furthermore, several large pharmaceutical companies have announced that they will “pull the plug on drug discovery in some areas of neuroscience” (Miller, 2010 , p.”
BackgroundRe-energizing the Development of Pain Therapeutics in Light of the Opioid Epidemic
Skolnick, P., & Volkow, N. D. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.051 · Cited by 59 · see citing works
“…retreat from neuroscience drug development, Andrew Witty, the CEO of GlaxoSmithKline, explained the termination of neuroscience (including pain) programs as areas where ‘‘ . the probability of success is relatively low. and the cost of attaining success is disproportionately high’’ (Miller, 2010).”
BackgroundInfluentialThe Secrets of a Successful Clinical Trial: Compliance, Compliance, and Compliance
Czobor, P., & Skolnick, P. (2011) · Molecular Interventions · doi:10.1124/mi.11.2.8 · Cited by 59 · see citing works
The failure of the antidepressant drug discovery process is systemic
Hendrie, C. A., & Pickles, A. R. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112466185 · Cited by 58 · see citing works
“Email: c.a.hendrie@leeds.ac.uk no longer going to vigorously pursue this goal (Miller, 2010).”
BackgroundProductivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?
Williams, M. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.171751 · Cited by 58 · see citing works
“The more targets, the more compounds, the more data sets, the greater the opportunity for success (Fryburg, 2010; Miller, 2010).”
BackgroundSchleim, S., & Quednow, B. B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00003 · Cited by 56 · see citing works
“…companies closed their respective laboratories and rather invested in other fields because of the lack of successes of newly developed compounds resulting in high business risks regarding the introduction of new medications (Miller, 2010; Nutt and Goodwin, 2011; van Gerven and Cohen, 2011).”
BackgroundMofsen, A. M., Rodebaugh, T. L., Nicol, G. E., Depp, C. A., Miller, J. P., & Lenze, E. J. (2019) · JMIR Mental Health · doi:10.2196/11845 · Cited by 51 · see citing works
“This has resulted in decreased investment in drug discovery [5].”
The Current State of Drug Discovery and a Potential Role for NMR Metabolomics
Powers, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401803b · Cited by 53 · see citing works
Mingrone, A., Kaffman, A., & Kaffman, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.618593 · Cited by 50 · see citing works
Recent advances in blood-brain barrier-on-a-chip models
Vetter, J., Palagi, I., Waisman, A., & Blaeser, A. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.03.041 · Cited by 55 · see citing works
Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System
Srinivas, N., Maffuid, K., & Kashuba, A. D. M. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0632-y · Cited by 49 · see citing works
From blood to brain: blood cell-based biomimetic drug delivery systems
Li, Y., Wu, J., Liu, J., Qiu, X., Xu, W., Tang, T., & Xiang, D. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1937384 · Cited by 46 · see citing works
“It has been reported that transcytosis may be the mechanism underlying the BBB-breaching process of exosomes (Morad et al., 2019).”
BackgroundThe Role of Regulators in Mitigating Uncertainty within the Valley of Death
Roca, J. B., & O’Sullivan, E. (2019) · Technovation · doi:10.1016/j.technovation.2020.102157 · Cited by 46 · see citing works
Drug repurposing for immune modulation in acute ischemic stroke
Amantea, D., & Bagetta, G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.11.006 · Cited by 46 · see citing works
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants
Niciu, M. J., Mathews, D. C., Nugent, A. C., Ionescu, D. F., Furey, M. L., Richards, E. M., Machado-Vieira, R., & Zarate, C. A. (2014) · Depression and Anxiety · doi:10.1002/da.22224 · Cited by 45 · see citing works
“[3] There have been successes in biomarker-driven drug development in the medical subspecialties, but early phase II failures continue to plague drug development in mood disorders due to the following: high attrition rates, long lead-time development, disease heterogeneity and inadequate mechanistic understanding of a…”
BackgroundInfluentialWhen less is more – microRNAs and psychiatric disorders
Kolshus, E., Dalton, V. S., Ryan, K. M., & McLoughlin, D. M. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12191 · Cited by 44 · see citing works
Systems biology, complexity, and the impact on antiepileptic drug discovery
Margineanu, D. G. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.08.029 · Cited by 43 · see citing works
Pickersgill, M. D. (2019) · Science Technology & Human Values · doi:10.1177/0162243919841693 · Cited by 55 · see citing works
“One possible motivation for RDoC is a much-discussed shift away from drug discovery for mental ill-health by the pharmaceutical industry (see Miller 2010).”
BackgroundSimão, D. F., Pinto, C., Piersanti, S., Weston, A., Peddie, C. J., Bastos, A. E. P., Licursi, V., Schwarz, S. C., Collinson, L., Salinas, S., et al. (2014) · Tissue Engineering Part A · doi:10.1089/ten.tea.2014.0079 · Cited by 41 · see citing works
“The study of central nervous system (CNS) disorders, such as Parkinson’s disease (PD), would particularly benefit from the development of more accurate cellular models, since only about 8% of new drugs that enter clinical trials are approved and reach the market.(3) In the case of PD, the available chemical or genetic…”
Imaging of human differentiated 3D neural aggregates using light sheet fluorescence microscopy
Gualda, E. J., Simão, D. F., Pinto, C., Alves, P. M., & Brito, C. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00221 · Cited by 41 · see citing works
The Need for Treatment Responsive Translational Biomarkers in Alcoholism Research
Heilig, M. A., Sommer, W. H., & Spanagel, R. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5006 · Cited by 42 · see citing works
Dimensional thinking in psychiatry in the era of the Research Domain Criteria (RDoC)
Kelly, J. R., Clarke, G. A., Cryan, J. F., & Dinan, T. G. (2017) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2017.7 · Cited by 39 · see citing works
“Major pharmaceutical companies have shifted drug discovery efforts away from psychiatric towards non-psychiatric disorders with identified biological targets (Miller, 2010).”
BackgroundAddressing the Genetics of Human Mental Health Disorders in Model Organisms
McCammon, J. M., & Sive, H. L. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-050048 · Cited by 40 · see citing works
Tran, B. X., Ha, G. H., Vu, G. T., Nguyen, L. H., Latkin, C. A., Nathan, K., McIntyre, R. S., Ho, C. S. H., Tam, W., & Ho, R. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16132255 · Cited by 38 · see citing works
Neuropharmacology beyond reductionism – A likely prospect
Margineanu, D. G. (2015) · Biosystems · doi:10.1016/j.biosystems.2015.11.010 · Cited by 38 · see citing works
Wahłsten, D. (2012) · Developmental Psychobiology · doi:10.1002/dev.21043 · Cited by 36 · see citing works
“The Chief Executive of GSK remarked that in the domains of pain, depression and anxiety ‘‘we believe the probability of success is relatively low, [and] we think the costs of attaining success is disproportionately high’’ (Miller, 2010).”
Tracking the impact of translational research in psychiatry: state of the art and perspectives
Machado‐Vieira, R. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-175 · Cited by 36 · see citing works
“Two major companies, GlaxoSmithKline and AstraZeneca [27], recently reduced significantly basic research aimed at developing new agents for psychiatric disorders.”
BackgroundXu, R., & Wang, Q. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.06.027 · Cited by 33 · see citing works
“Despite the vast unmet medical need, many drug companies have moved away from SCZ drug development, in part because of the high costs, high failure rates in clinical trials, lengthy development processes, and a poor understanding of underlying mechanisms of the disease [5, 6, 7].”
BackgroundReal-Time Functional MRI in the Treatment of Mental Health Disorders
Taschereau‐Dumouchel, V., Cushing, C. A., & Lau, H. C. (2022) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072220-014550 · Cited by 33 · see citing works
Wasko, M. J., Pellegrene, K. A., Madura, J. D., et al. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00197 · Cited by 33 · see citing works
“…SERT, serotonin transporter protein; VHTS, virtual high-throughput screening; VS, virtual screening. companies to drastically limit research expenses, and while outsourcing is an option carrying benefits and liabilities (3), development of new, more cost-effective drug design methods is a priority.”
BackgroundElevating the Role of Subjective Experience in the Clinic: Response to Fanselow and Pennington
Pine, D. S., & LeDoux, J. E. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17070818r · Cited by 31 · see citing works
Wortzel, J. R., Turner, B. E., Weeks, B. T., Fragassi, C., Ramos, V., Truong, T., Li, D., Sahak, O., & Lee, H. B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233996 · Cited by 31 · see citing works
“Multiple international pharmaceutical companies have significantly decreased their investments in new treatments for depression, bipolar disorder, and schizophrenia, and some companies, such as GlaxoSmithKline, have closed their psychiatric units altogether [18, 19].”
BackgroundKaye, J. T., Bradford, D. E., Magruder, K. P., & Curtin, J. J. (2017) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2017.78.353 · Cited by 29 · see citing works
“…weigh against further exploration, including growing concern about translation of preclinical findings to humans (Insel, 2012; Kapur et al., 2012; Miller, 2010), the previous failures of CRF1 antagonists in phase 3 trials with clinical outcomes for mood and anxiety disorders (Binneman et al.,…”
BackgroundEnhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development
Kaffman, A., White, J. D., Wei, L., Johnson, F. K., & Krystal, J. H. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_1 · Cited by 31 · see citing works
Deep history and beyond: a reply to commentators
LeDoux, J. E. (2023) · Philosophical Psychology · doi:10.1080/09515089.2022.2160312 · Cited by 31 · see citing works
“This approach has resulted in decades of disappointing treatments, such that by 2010 pharmaceutical companies had started reducing efforts in mental health research (Hyman, 2013; Miller, 2010).”
BackgroundScientific process, pharmacology and drug discovery
Trist, D. G. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.05.008 · Cited by 30 · see citing works
Mäki‐Marttunen, T., Kaufmann, T., Elvsåshagen, T., Devor, A., Djurovic, S., Westlye, L. T., Linne, M., Rietschel, M., Schubert, D., Borgwardt, S., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00534 · Cited by 31 · see citing works
Mingote, S., Masson, J., Gellman, C., Thomsen, G. M., Lin, C., Merker, R. J., Gaisler‐Salomon, I., Wang, Y., Ernst, R., Hen, R., et al. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2015.00165 · Cited by 29 · see citing works
“The dearth of new psychiatric drugs over the past decades underpins the vastly unmet need for better treatments (Brundtland, 2001; Miller, 2010).”
BackgroundKishimoto, T., Takamiya, A., Liang, K., Funaki, K., Fujita, T., Kitazawa, M., Yoshimura, M., Tazawa, Y., Horigome, T., Eguchi, Y., et al. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100649 · Cited by 30 · see citing works
“Failures in such clinical trials have even led to the unfortunate consequence of several pharmacological companies moving out of the psychiatric field [3, 4].”
Background
- Authors
- Miller, G.
- Corresponding author
- Miller, Greg
- Venue
- Science
- Published
- 2010-07-30
- Volume
- 329
- Issue
- 5991
- Pages
- 502-504
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075757880
- Cited by
- 284
- References
- 0
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 13 · 2023: 11 · 2022: 24 · 2021: 14 · 2020: 12 · 2019: 23 · 2018: 15 · 2017: 25 · 2016: 11 · 2015: 25 · 2014: 18 · 2013: 21 · 2012: 31
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- drug development, neurological disorders, pharmaceutical industry, research funding cuts, brain research, neuropharmacology
- MeSH terms
- Mental Disorders, Central Nervous System Agents, Central Nervous System Diseases, Clinical Trials as Topic, Drug Industry, Humans, Drug Approval, Access to Information, Biomedical Research, Drug Discovery, Public-Private Sector Partnerships
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
